Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome
NCT06291194Phase 3Recruiting
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Nov 2023
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoint: Total Corneal Staining Score at Week 12. Started Nov 2023; status: recruiting.
02
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT06291194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291194.